麦克森McKesson Corporation (MCK) 2021年年度报告「NYSE」.pdf

1、Annual Report|Fiscal Year Ended March 31,2021The moments that matteredDistribution ScaleDelivered 1/3 of all prescription medicines inNorth America Delivered medical-surgical supplies and services to275,000+customers10,500 owned and banner pharmacies acrossCanada andEurope Superior Specialty AssetsU

2、S Oncology Research has played a role in 100+FDAapproved cancer therapiesMcKesson supported over 14,000 specialty physicians through distribution and GPO services#1 distributor in community oncology andkeyspecialtiesBiopharma ServicesMore than 500 biopharma brands servedIncreased value to biopharma

3、and enabled$5Binprescription savingsSupported over 94%of therapeutic areasTechnology Differentiation19B+annual pharmacy transactions processedthrough RelayHealthConnected to payers representing 94%of U.S.prescriptionvolumeNetwork of 750,000+providers and over50,000pharmaciesOne package,one patient,o

4、nemoment at atimewe deliveredLast year,I wrote my annual letter to you at the very onset of COVID-19.Since then,McKesson has played a front and center role to help end the pandemicworking in partnership with our customers and interacting with regulatory authorities and other leading companies to bri

5、ng personal protective equipment,medications and essential supplies to healthcare facilities and first responders;leveraging our lab capabilities to ramp up the distribution of COVID-19 tests as they came to market;and most recently,having the honor of serving as the centralized distributor of COVID

6、-19 vaccines and the ancillary kits needed to administer them.Through April,weve successfully distributed over 150 million Moderna and Johnson&Johnson COVID-19 vaccines and have assembled enough kits to support the administration of more than 550 million doses of all vaccine types.Even now,we contin